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Parthenolide (1) is a lipophilic, neutral lactone with low

USE OF PARTHENOLIDE DERIVATIVES AS
ANTILEUKEMIC AND CYTOTOXIC AGENTS

polarity, and has a low water-solubility, limiting its develop
ment as a therapeutic agent. Thus, a need exists for the devel

This is a divisional application of US. patent application
Ser. No. 12/693,161, ?led Jan. 25, 2010, now US. Pat. No.
8,124,652, which is a divisional application of US. patent
application Ser. No. 11/031,315 ?led Jan. 7, 2005, now US.
Pat. No. 7,678,904, which is a continuation-in-part of US.

opment of soluble parthenolide derivatives that retain their

patent application Ser. No. 10/888,274 ?led Jul. 9, 2004, now
US. Pat. No. 7,312,242, which claims the bene?t of priority
to provisional application No. 60/486,171 ?led Jul. 11, 2003.

compounds with antileukemic activity is presented. Accord
ingly, the present invention provides compounds of formula

anti-cancer activity.
SUMMARY OF THE INVENTION

In accordance with the present invention, a novel class of

(I):

FIELD OF THE INVENTION

(I)

The present invention relates to methods for the structural

modi?cation of the sesquiterpene lactone, parthenolide, and
the use of these parthenolide derivatives in the treatment of
carcinoma. More speci?cally, the invention relates to the
methods to prepare structural analogs of the parent com

20

pound, parthenolide, in order to obtain new, pharmacologi
cally active chemical entities with improved water solubility
characteristics, and to use them in the treatment of leukemias

and other parental and multi-drug resistant cancers
25

BACKGROUND OF THE INVENTION

wherein:

X1, X2 and X3 are heteroatoms;

R4, R5, R6, R7, R8, R9 and R10 are independently selected

Sesquiterpene lactones are a group of secondary plant
metabolites consisting of a 15-carbon structure containing an

(x-methylene-y-butyrolactone moiety and other additional

30

functional groups. Over the last two to three decades, these

terpenoids have received considerable attention due to the
broad spectrum of their biological activities, to the plants
which produce them, and most importantly, because of their
pharmacological effects in humans. About 4,000 of these
terpenoids have been isolated and identi?ed, most of them in

Z is optionally substituted C 1_8 straight-chained or branched
aliphatic, optionally containing 1 or more double or triple
bonds, wherein one or more carbons are optionally replaced
35

been used for centuries in indigenous medical practices in

different species in Asteraceae (Compositae) family, fever
few (Tanacetum parthenium) being one of them.

by R* wherein R* is optionally substituted cycloalkyl, het
erocycloalkyl, aryl or heteroaryl; an amino acid residue, H,

4CN, iC(O)i, 4C(O)C(O)i, 4C(O)NRli, 4C(O)
NRlNRzi, iC(O)Oi, wqok, iNRlCOZi,
wi, iNR1C(O)NRZi, iOC(O)NRli, iNRlNRZi,

Asteraceae (Compositae, sun?ower family) (Schmidt, Curr.
Org. Chem. 1999, 3, 577-608). Some of these plants have
various cultures worldwide.
Parthenolide (1) is a Germacrane sesquiterpene lactone
with a unique structure. It has been isolated from several

from H, halo, 40H, iNOZ, 4CN and optionally substi
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het
eroaryl; and

40

iNRlC(O)i, isi, isoi, isor, iNRli,
iSOzNRli, iNRlR2, or iNRlSOZi, wherein R1 and
R2 are independently selected from H and optionally substi

tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het
eroaryl; or where R* is NRIRZ, R1 and R2 optionally together
45

50

with the nitrogen atom form an optionally substituted 5-12
membered ring, said ring optionally comprising 1 or more
heteroatoms and/or a group selected from iCOi, iSOi,
iSOZi and iPOi; or
a pharmaceutically acceptable salt, ester or prodrug
thereof.

The invention also provides a pharmaceutical composition
comprising an effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt, ester or prodrug

thereof, in combination with a pharmaceutically acceptable
55

diluent or carrier.

The invention also provides a method of inhibiting cancer

cell growth and metastasis of cancer cells, comprising admin

Feverfew has been used to reduce fever and pain and in the
treatment of mi graine and rheumatoid arthritis (Heptinstall et

al., ACS Symposium Series (1998), 691 (Phytomedicines of
Europe), 158-175.). The active component is parthenolide
(1). Recently, it has been revealed that parthenolide (1) can

istering to a mammal af?icted with cancer, an amount of a

compound of formula (I), effective to inhibit the growth of
60

The invention also provides a method comprising inhibit
ing cancer cell growth by contacting said cancer cell in vitro

induce tumor apoptosis by the inhibition of NF-KB activities

(Cory et al., Anticancer Research 2002, 22, 3805-9; Cory et
al., Anticancer Research 2001, 21, 3807-11; Gelfanov et al.,
Blood, 2000, 98, 2508-17; Kang et al, Brit. J. Pharmacol.
2002, 135, 1235-44; Song et al., J. Asian. Nat. Prod. Res.

2001, 3, 285-91).

said cancer cells.

or in vivo with an amount of a compound of formula (I),
effective to inhibit the growth of said cancer cell.
65

The invention also provides a compound of formula (I) for
use in medical therapy (preferably for use in treating cancer,
e.g. solid tumors), as well as the use of such compound for the

US 8,470,875 B2
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manufacture of a medicament useful for the treatment of
cancer and other diseases/ disorders described herein.

and each substitution is independent of any other. Also, com
binations of substituents or variables are permissible only if
such combinations result in stable compounds. In addition,
unless otherwise indicated, functional group radicals are

The invention further provides methods of treating in?am
matory diseases and disorders, including, for example, rheu
matoid arthritis, osteoarthritis, allergies (such as asthma), and

independently selected. Where “optionally substituted”
modi?es a series of groups separated by commas (e. g.,
“optionally substituted A, B or C”; or “A, B or C optionally
substituted with”), it is intended that each of the groups (e. g.,

other in?ammatory conditions, such as pain (such as

migraine), swelling, fever, psoriasis, in?ammatory bowel dis
ease, gastrointestinal ulcers, cardiovascular conditions,
including ischemic heart disease and atherosclerosis, partial
brain damage caused by stroke, skin conditions (eczema,
sunburn, acne), leukotriene-mediated in?ammatory diseases

A, B and C) is optionally substituted.
The term “aliphatic” or “aliphatic group” as used herein
means a straight-chain or branched C 1_l 2 hydrocarbon chain
that is completely saturated or that contains one or more units

of lungs, kidneys, gastrointestinal tract, skin, prostatitis and

paradontosis.

of unsaturation, or a monocyclic C3_8 hydrocarbon orbicyclic

The invention further provides methods of treating
immune response disorders, whereby the immune response is
inappropriate, excessive or lacking. Such disorders include

C8_12 hydrocarbon that is completely saturated or that con
tains one or more units of unsaturation, but which is not

allergic responses, transplant rejection, blood transfusion

“cycloalkyl”), that has a single point of attachment to the rest
of the molecule wherein any individual ring in said bicyclic

aromatic (also referred to herein as “carbocycle” or

reaction, and autoimmune disorders such as systemic lupus
erythematosus and rheumatoid arthritis.

ring system has 3-7 members. For example, suitable aliphatic
20

FIG. 1 shows the effectiveness of parthenolide and deriva
tives of the present invention against prostate cancer cell line
CWR22 in a clonogenic assay.
FIG. 2 shows the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
A-549 in a cellular proliferation MTS-PMS assay.
FIG. 3 shows the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
H-522 in a cellular proliferation MTS-PMS assay.
FIG. 4 shows the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
H-23 in a cellular proliferation MTS-PMS assay.
FIG. 5 shows the effectiveness of parthenolide and deriva
tives of the present invention against lung cancer cell line
H-460 in a cellular proliferation MTS-PMS assay.
FIG. 6 shows the effectiveness of parthenolide and deriva
tives of the present invention against breast cancer cell line
HBL-lOO in a clonogenic assay.
FIG. 7 shows the effectiveness of parthenolide and deriva
tives of the present invention against breast cancer cell line
MD-23l in a clonogenic assay.
FIG. 8 shows the effectiveness of parthenolide and deriva
tives of the present invention against breast cancer cell line
MD-436 in a clonogenic assay
FIG. 9 shows parthenolide and DMAPT plasma concen
trations at one hour following oral gavage in mice.
FIG. 10 shows DMAPT dose-dependent inhibition of NF
kB DNA binding in two transitional cell carcinoma cell lines

enyl.
The terms “alkyl,” “alkoxy,” “hydroxyalkyl,” “alkoxy
25

one to twelve carbon atoms. The terms “alkenyl” and “alky
nyl” used alone or as part of a larger moiety shall include both
straight and branched chains containing two to twelve carbon
30 atoms.

The terms “haloalkyl,” “haloalkenyl” and “haloalkoxy”
means alkyl, alkenyl or alkoxy, as the case may be, substituted
with one or more halogen atoms. The term “halogen” or
35

“halo” means F, Cl, Br or I.
The term “heteroatom” means nitrogen, oxygen, or sulfur

and includes any oxidized form of nitrogen and sulfur, and the
quatemized form of any basic nitrogen. Heteroatom further
includes Se, Si and P.
The term “aryl” used alone or in combination with other
40

45

terms, refers to monocyclic, bicyclic or tricyclic carbocyclic
ring systems having a total of ?ve to fourteen ring members,
wherein at least one ring in the system is aromatic and
wherein each ring in the system contains 3 to 8 ring members.
The term “aryl” may be used interchangeably with the term
“aryl ring”. The term “aralkyl” refers to an alkyl group sub
stituted by an aryl. The term “aralkoxy” refers to an alkoxy
group substituted by an aryl.

The term “heterocycloalkyl,” “heterocycle,” “heterocy
clyl” or “heterocyclic” as used herein means monocyclic,
50

bicyclic or tricyclic ring systems having ?ve to fourteen ring
members in which one or more ring members is a heteroatom,

wherein each ring in the system contains 3 to 7 ring members
and is non-aromatic.

FIG. 11 shows FSCScan analysis of TRAIL induced apo
ptosis assay using MDA-MB-23l breast cancer cells treated

The term “heteroaryl,” used alone or in combination with
55

other terms, refers to monocyclic, bicyclic and tricyclic ring
systems having a total of ?ve to fourteen ring members, and
wherein: l) at least one ring in the system is aromatic; 2) at

FIG. 12 shows FSCScan analysis of TRAIL induced apo
ptosis assay using MDA-MB-23l breast cancer cells treated
?rst with DMAPT, then TRAIL.
DETAILED DESCRIPTION OF THE INVENTION

alkyl” and “alkoxycarbonyl,” used alone or as part of a larger

moiety include both straight and branched chains containing

HT-l376 and UMUC-3 in electrophoretic mobility gel shift
assay (EMSA).
?rst with DMAPT, then TRAIL-RII-activating antibodies.

groups include, but are not limited to, linear or branched or

alkyl, alkenyl, alkynyl groups and hybrids thereof such as
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alk

BRIEF DESCRIPTION OF THE DRAWINGS

least one ring in the system contains one or more heteroatoms;
60

and 3) each ring in the system contains 3 to 7 ring members.
The term “heteroaryl” may be used interchangeably with the
term “heteroaryl ring” or the term “heteroaromatic”.

Examples of heteroaryl rings include 2-furanyl, 3-furanyl,

As used herein, the following de?nitions shall apply unless
otherwise indicated.

The phrase “optionally substituted” is used interchange
ably with the phrase “substituted or unsubstituted.” Unless
otherwise indicated, an optionally substituted group may
have a substituent at each substitutable position of the group,

65

N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl,
3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl,
5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, l-pyrro
lyl, 2-pyrrolyl, 3-pyrrolyl, l-pyrazolyl, 3-pyrazolyl, 4-pyra
zolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrim

US 8,470,875 B2
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5
idyl, 5-pyrimidyl, 3-pyridaZinyl, 2-thiazolyl, 4-thiazolyl,
5-thiazolyl, 5-tetrazolyl, 2-triazolyl, 5-triazolyl, 2-thienyl,
3-thienyl, carbazolyl, benZimidazolyl, benzothienyl, benzo
furanyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl,
benzooxazolyl, benZimidazolyl, isoquinolinyl, indazolyl,

phatic), iOH, 4Oi(Cl_4 aliphatic), iNOZ, iCN,
4CO2H, iCO2(Cl_4 aliphatic), iO(halo Cl_4 aliphatic)
or -halo(C1_4 aliphatic); wherein each C1_4 aliphatic is option
ally substituted.
The term “linker group” or “linker” means an organic

isoindolyl, acridinyl, and benzoisoxazolyl. The term “het

moiety that connects two parts of a compound. Linkers
include alkylidene chain that is a saturated or unsaturated,

eroaralkyl” refers to an alkyl group substituted by a het
eroaryl. The term “heteroarylalkoxy” refers to an alkoxy
group substituted by a heteroaryl. \

straight or branched, C1_8 carbon chain which is optionally
substituted, and wherein up to two non-adjacent saturated
carbons of the chain are optionally replaced by R* wherein

An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the
like) or heteroaryl (including heteroaralkyl, heteroarylalkoxy

R* is %(O)i, %(O)C(O)i, iC(O)NRi, %(O)
NRNRi, %(O)Oi, iOC(O)i, iNRCOZi, ADi,
iNRC(O)NRi, iOC(O)NRi, iNRNRi, iNRC

and the like) group may contain one or more substituents.
Suitable substituents on an unsaturated carbon atom of an

aryl, heteroaryl, aralkyl or heteroaralkyl group are selected

(O)i, iSi, iSOi, iSOZi, iNRi, iSOZNRi, or

from halogen; haloalkyl; 4CF3; iR; iOR; iSR; 1,2

iNRSOZi; wherein R is selected from hydrogen or option

methylenedioxy; 1,2-ethylenedioxy; protected OH (such as
acyloxy); phenyl (Ph); Ph substituted with R; iO(Ph); *0
(Ph) substituted with R; 4CH2(Ph); 4CH2(Ph) substituted
with R; iCHZCH2(Ph); iCHzCH2(Ph) substituted with R;

or heteroaryl, and preferably H or optionally substituted C l_4
aliphatic. Optional substituents on the alkylidene chain are as

iNOZ; %N; iN(R)2; *NRC(O)R; iNRC(O)N(R)2;

ally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl

20

25

i(CH2)yNHC(O)R; i(CH2)yR; i(CH2)yNHC(O)NHR;
i(CH2)yNHC(O)OR; i(CH2)yNHS(O)R; i(CH2)y

logic condition in a mammal, particularly a human, and
includes: (i) preventing the pathologic condition from occur
ring in a subject which may be predisposed to the condition
but has not yet been diagnosed with the condition and, accord
ingly, the treatment constitutes prophylactic treatment for the

disease condition; (ii) inhibiting the pathologic condition,
i.e., arresting its development; (iii) relieving the pathologic
condition, i.e., causing regression of the pathologic condi

NHSOZR; or i(CH2)yNHC(O)CH((V)ZiR)(R) wherein
each R is independently selected from hydrogen, optionally
substituted Cl_6 aliphatic, an unsubstituted 5-6 membered

described above for an aliphatic group. Alternatively, the
linker group is R*.
The term “treatment” refers to any treatment of a patho

30

heteroaryl or heterocyclic ring, phenyl (Ph), 40(Ph), or

tion; or (iv) relieving the conditions mediated by the patho
logic condition.

iCH2(Ph)-CH2(Ph), wherein y is 0-6; Z is 0-1; and V is a

The term “therapeutically effective amount” refers to that

linker group. When R is C 16 aliphatic, it may be substituted

amount of a compound of the invention that is suf?cient to
effect treatment, as de?ned above, when administered to a

with one or more substituents selected from iNHZ, iNH

(C 1_ 4 aliphatic), iN(C1_4 aliphatic)2, iS(O)(Cl_4 aliphatic),

35

iSOZ(C1_4 aliphatic), halogen, (Cl_4 aliphatic), iOH,
iO(Cl_4 aliphatic), iNOZ, iCN, iCO2H, 4COZ(C1_4

condition being treated, the weight and age of the subject, the

aliphatic), 40(halo C1_4 aliphatic), or -halo(Cl_4 aliphatic);
wherein each C1_4 aliphatic is optionally.
An aliphatic group or a non-aromatic heterocyclic ring

40

is not limited to, salts well known to those skilled in the art, for

aromatic heterocyclic ring are selected from those listed
above for the unsaturated carbon of an aryl or heteroaryl
45

:Ni, :NNHC(O)R, :NNHCOZ(alkyl), :NNHSO2
(alkyl), or :NR, where each R is independently selected
from hydrogen or an optionally substituted C1_6 aliphatic.
When R is Cl_6 aliphatic, it may be substituted with one or
more substituents selected from iNHZ, iNH(Cl_4 ali

50

administration of the compounds as salts may be appropriate.
55

Examples of pharmaceutically acceptable salts are organic
acid addition salts formed with acids that form a physiologi

iR, iN(R)2, iC(O)R, iC(O)OR, 4C(O)C(O)R,
iC(O)CH2C(O)R, iSOZR, iSOZN(R)2, 4C(:S)N(R)2,
iC(:NH)iN(R)2 or iNRSOZR; wherein each R is inde
60

Cl_6 aliphatic, optionally substituted phenyl (Ph), optionally
substituted 40(Ph), optionally substituted 4CH2(Ph),
optionally substituted 4CH2CH2(Ph), or an unsubstituted
5-6 membered heteroaryl or heterocyclic ring. When R is a
C1_6 aliphatic group or a phenyl ring, it may be substituted

iP(:O)(OH)i, is replaced with a pharmaceutically
acceptable cation (e.g. a sodium, potassium, or ammonium
ion) and can be conveniently be prepared from a correspond
ing compound of formula (I) by, for example, reaction with a
suitable base. In cases where compounds are suf?ciently
basic or acidic to form stable nontoxic acid or base salts,

iO(halo C1_4 aliphatic), or -halo(Cl_4 aliphatic); wherein

pendently selected from hydrogen, an optionally substituted

example, mono-salts (e.g. alkali metal and ammonium salts)
and poly salts (e.g. di- or tri-salts,) of the compounds of the
invention. Pharmaceutically acceptable salts of compounds
of formulas (I), (II), (III), or (IV) are where, for example, an
exchangeable group, such as hydrogen in iOH, iNHi, or

phatic), iN(C1_4 aliphatic)2, halogen, 40H, iOi(Cl_4
aliphatic), iNOZ, 4CN, iCOZH, 4COZ(C1_4 aliphatic),
each C 1_ 4 aliphatic is optionally substituted.
Substituents on a nitrogen of a non-aromatic heterocyclic
ring are selected from

severity of the disease condition, the manner of administra
tion and the like, which can readily be determined by one of
ordinary skill in the art.

The term “pharmaceutically acceptable salts” includes, but

may contain one or more substituents. Suitable substituents
on a saturated carbon of an aliphatic group or of a non

group and the following: :0, :S, :NNHR, :NN(R)2,

mammal in need of such treatment. The therapeutically effec
tive amount will vary depending upon the subject and disease

cal acceptable anion, for example, tosylate, methane
sulfonate, acetate, citrate, malonate, tartarate, succinate, ben
zoate, ascorbate, (x-ketoglutarate, and (x-glycerophosphate.
Suitable inorganic salts may also be formed, including hydro
chloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts include quaternary
ammonium salts formed with R'Y; where Y is selected from

halogen, tosylate, methanesulfonate, benzenesulfonate, trif
65

luoromethanesulfonate and the like; and R' is selected from

with one or more substituents selected from iNHZ, iNH

an optionally substituted cycloalkyl, heterocycloalkyl, aryl or

(Cl_4 aliphatic), iN(C1_4 aliphatic)2, halogen, i(Cl_4 ali

heteroaryl.
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Suitable acids include hydro?uoric acid, hydrochloric
acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric
acid, phosphoric acid, carbonic acid, boric acid, selenious

Antiviral Chem & Chemo. 12: 293-300; Knaggs et al., 2000
Bioorganic & Med. Chem. Letters 10: 2075-2078) each of

which is incorporated in their entirety herein by reference.
The invention relates to the ability of the (x-methylene-y
butyrolactone moiety in sesquiterpene lactones to be struc
turally modi?ed by, for example, Michael addition with

acid, hydrogen sul?de, phosphomolybdic acid, phosphorous
acid, sulfurous acid, citric acid, maleic acid, D-malic acid,
L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, meth
anesulfonic acid, valeric acid, oleic acid, lauric acid, para

amines or thiols. Modi?cation of the parthenolide (1) mol

toluenesulfonic acid, 1-naphthalensulfonic acid, 2-naphtha

ecule by this methodology using primary and/or secondary

lensulfonic acid, phthalic acid, tartaric acid, L-malic acid,
DL-malic acid, malonic acid, succinic acid, fumaric acid,

amines to form water-soluble amino derivatives, affords
amine adducts that can easily be obtained as different inor
ganic or organic salts to further increase water solubility.

glycolic acid, thioglycolic acid, glycine, sarcocine, sulfonic
acid, nicotinic acid, picolinic acid, isonicotinic acid, benzoic

Thus, a novel class of more water-soluble parthenolide ana

acid and substituted benzoic acid where benzene ring bears

logs is described. When compounds in this class were evalu

one or more substituents.

ated for antileukemic activity, it was found that these com
pounds were either equipotent as, or more potent than the

Pharmaceutically acceptable salts may be obtained using
standard procedures well known in the art, for example, by

parent compound, parthenolide. More importantly, these
novel analogs showed greater cytotoxicity towards leukemia

reacting a suf?ciently basic compound such as an amine with
a suitable acid affording a physiologically acceptable anion.

Alkali metal (for example, sodium, potassium or lithium) or
alkaline earth metal (for example, calcium) salts of carboxy

20

lic acids can also be made.

cells than towards normal cells. Thus, the present invention
provides a new class of parthenolide derivatives with potent
and selective anticancer activities.
In accordance with the present invention, there are pro

vided compounds of formula (I):

The term “prodrug” or “prodrugs” is used in its ordinary
meaning in the art and means a compound of the invention

that has its charged moieties masked or protected by another
moiety that is designed to be cleaved under particular physi

(I)

25

ological conditions, leaving the deprotected or unmasked
compound of the invention. The use of masking agents is
common and well-known in the art and, in particular, masking

phosphate or phosphonate groups. All such masking agents
are suitable and can be used with the compounds of the
invention. Various agents such as acyloxy alkyl esters are

30

described by Srivasta et al., (1984 Bioorganic Chemistry 12,
118-12), and by Freeman et al. (1997 Progress in Medicinal
Chemistry 34:112-147) which are each incorporated in their

entirety herein by reference; and 3-phthalidyl phosphonate
esters are described by Dang Q, et al., (1999 Bioorganic &
Med. Chem. Letters, 9:1505-1510), which is incorporated in
its entirety herein by reference. For example, and not by way
of limitation, Srivasta et al. also describe acetoxymethyl,
isobutryloxymethyl, and pivaloxymethyl as masking agents.

35

wherein:

e.g., pivaloxymethyl, or a pivaloyloxy group as described by

X1, X2 and X3 are heteroatoms;
R4, R5, R6, R7, R8, R9 and R10 are independently selected
from H, halo, 40H, iNOZ, 4CN and optionally substi
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het
eroaryl; and
Z is optionally substituted Cl_8 straight-chained or

Farquhar D. et al., (1995 J. Med. Chem., 38:488-495) which
is incorporated in its entirety herein by reference. Still other

branched aliphatic, optionally containing 1 or more double or
triple bonds, wherein one or more carbons are optionally

40

Other suitable masking groups comprising pivaloxyalkyl,

masking or protecting agents are described in US. Pat. Nos.
4,816,570 and 4,968,788 both of which are incorporated in

45

replaced by R* wherein R* is optionally substituted
cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino

their entirety herein by reference. Lipid prodrugs are also

acid residue, H, 4CN, iC(O)i, iC(O)C(O)i, 4C(O)

suitable for use with the compounds of the invention. By

NRli, iC(O)NR1NRZi, %(0)oi, wqok,
iNRlCOZi, 40*, iNR1C(O)NRZi, iOC(O)NRli,
iNRlNRZi, iNRlC(O)i, isi, isoi, isozi,

non-limiting example, certain lipid prodrugs are described in
Hostetler et al., (1997 Biochem. Pharm. 53:1815-1822), and

50

iNRli, iSOZNRli, iNRlRZ, or iNRlSOzi,

Hostetler et al., 1996 Antiviral Research 31:59-67), both of
which are incorporated in their entirety herein by reference.

wherein R1 and R2 are independently selected from H and

Additional examples of suitable prodrug technology is

optionally substituted aliphatic, cycloalkyl, heterocycloalkyl,

described in WO 90/00555; WO 96/39831; WO
03/095665A2; US. Pat. Nos. 5,411,947; 5,463,092; 6,312,
662; 6,716,825; and US. Published Patent Application Nos.
2003/0229225 and 2003/0225277 each of which is incorpo
rated in their entirety herein by reference. Such prodrugs may
also possess the ability to target the drug compound to a
particular tissue within the patient, e.g., liver, as described by
Erion et al., (2004 J. Am. Chem. Soc. 126:5154-5163; Erion et
al., Am. Soc. Pharm. & Exper. Ther. DOI: 10.1124/
jept.104.75903 (2004); WO 01/18013 A1; US. Pat. No.

aryl or heteroaryl; or where R* is NR1R2, R1 and R2 option
ally together with the nitrogen atom form an optionally sub

6,752,981), each of which is incorporated in their entirety
herein by reference. By way of non-limiting example, other
prodrugs suitable foruse with the compounds of the invention
are described in WO 03/090690; and by Harris et al., (2002

55

stituted 5-12 membered ring, said ring optionally comprising
1 or more heteroatoms and/ or a group selected from 4COi,

iSOi, iSOZi and iPOi; or
a pharmaceutically acceptable salt, ester or prodrug
60

thereof.

Presently preferred compounds include compounds of for
mula (I) wherein R5, R6, R7, R9 and R10 are independently
selected from H, halo, 40H, iNOZ, iCN, iCH3, 4CF3,

%H2CH3,
65

%H2CF3,

%H2Cl,

%HZOH,

4CH2CHZOH and 4CH2NH2. Further preferred embodi
ments include compounds where R5, R6, R7, R9 and R10 are
each H.
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l l S, l 1,13 -Dihydro, l 3-(heptamethyleneimin-l -yl)partheno

Other preferred embodiments of the present invention
include compounds Where R4 and R8 are independently
selected from optionally substituted Cl-C4 alkyl. In one pre

lide;
1 18,1 1,13 -Dihydro, l 3-(azetidin-l -yl)parthenolide;

ferred embodiment, R4 is 4CH3, and in another, R4 and R8

l l S, l l , l 3 -Dihydro, l 3-methylbutyl aminoparthenolide;

are each 4CH3.
In one embodiment X1, X2 and X3 are heteroatoms inde

l l S, l 1,13 -Dihydro, l 3-methyl pentyl aminoparthenolide;
1 18,1 1,13 -Dihydro, l 3-ethylaminoparthenolide;
l l S, l 1,13 -Dihydro, l 3-methylaminoparthenolide;
l l S, l 1,13 -Dihydro, l 3-cyclopropylaminoparthenolide;
1 18,1 1,13 -Dihydro, l 3-propargylaminoparthenolide;
l l S, l 1,13 -Dihydro, l 3-(N-benzyl-N-ethylamine)partheno

pendently selected from O, N and S, and in one particular
embodiment, X1, X2 and X3 are each 0.
According to one embodiment, it is preferred that Where

R5, R6, R7, R9 and R10 are H, R4 and R8 are each iCH3, and
X1, X2 and X3 are each 0; Z is not :CHZ.

lide;
1 18,1 1,13 -Dihydro, l 3-(N-prolyl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(S -thiophenolyl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(N,N-diethanolamine)parthenolide
l l S, l 1,13 -Dihydro, l 3-(thiomorpholin-4 -yl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(4 -hydroxypiperidin- l -yl)partheno

According to a further embodiment of the invention, Z is
i(CH2)miNR1R2 Where m is an integer from 0 to 4, Where

preferably, R5, R6, R7, R9, and R10 are H; and R4 and R8 are
each 4CH3. In one particular embodiment, m is 1. In other

embodiments, R1 and R2 are independently selected from
hydrogen, 4CN or optionally substituted C l-C4 alkyl. In
particular embodiments, R1 and R2 are independently

lide;
l l S, l 1,13 -Dihydro, l 3-(1 -methylhomopiperiZin-4 -yl)par

thenolide;

selected from iNOZ, 4CN, 4CH3, iCF3, iCHZCH3,

iCHZCF3, iCHzCl, iCHzOH, iCHzCHzOH and
iCHZNHZ.
In yet a further embodiment, R1 and R2 together With N
form an optionally substituted ring. The ring is a monocyclic,
bicyclic or tricyclic aliphatic or aryl ring system, Where the
ring system is optionally substituted and optionally com

20

parthenolide;
1 18,1 1,13 -Dihydro, l 3-(piperaZin-l -yl-4-carboxaldehyde)

parthenolide;
1 18,1 1,13 -Dihydro, l 3-(4 -benzylpiperidin- l -yl)partheno

prises one or more heteroatoms or a group selected from

iCOi, iSOi, iSOZi and iPOi. In one particular
embodiment, R1 and R2 are iCH2(CH2)nCH2Yi, WhereY

l l S, l 1,13 -Dihydro, l 3-(S -mercaptoacetyl)parthenolide;
l l S, l 1,13 -Dihydro, l 3-(4-(2'-hydroxyethyl)piperidin-l -yl)

25

lide;
1 18,1 1,13 -Dihydro, l 3-(piperidin-l -yl-4-carboxylic

parthenolide;

acid)

or tricyclic ring system, Where the system is optionally sub

1 18,1 1,13 -Dihydro, l 3-(azetidin-l -yl-3 -carboxylic acid)par
thenolide;
1 18,1 1,13 -Dihydro, l 3-(S-cysteinyl)parthenolide;
1 18,1 1,13 -Dihydro, l 3-(4-(piperidin- l '-yl)piperidin- l -yl))
parthenolide; and

stituted and optionally comprises one or more heteroatoms.

1 1S, 1 l ,13 -Dihydro, l 3-diallylaminoparthenolide.

is a heteroatom or a group selected from 4COi, iSOi,

iSOZi and iPOi; n is an integer 0 to 5; and together With
N form an optionally substituted ring, Which may be addi
tionally fused to a cycloalkyl or aryl group to form a bicyclic

30

Alternatively, R1 and R2 are i(CH2)aiYi(CH2)bi,

Those of skill in the art Will recognize that the invention

Where Y is a heteroatom or a group selected from 4COi,

comprises compounds that may contain one or more chiral

iSOi, iSOZi and iPOi; a is an integer 0 to 5; b is an
integer 0 to 5; Where the sum of a and b is 0 to 5; and together

35

With N form an optionally substituted ring, the ring being

clic or tricyclic ring system, Where the system is optionally
substituted and optionally comprise one or more heteroat
40

Examples of ring systems include an optionally substituted

als. Suitable stereoselective synthetic procedures for produc
ing stereochemically pure or optically pure materials are well
known in the art, as are procedures for resolving racemic
mixtures into their optically pure enantiomers.

uracil ring or a derivative thereof. Other examples include

optionally substitute pyrrole, imidazole, purine and pyrazole
and derivative thereof. Examples of fused ring systems

include optionally substituted aZiridin-l-yl, azetidin-l-yl,
pyrrolidin- l -yl, piperidin-l -yl, homopiperidyn- l -yl and hep
tamethyleneimin- l -yl.

exist as racemic mixtures as pure diastereomers, or as pure

enantiomers. For many applications, it is preferred to carry
out stereoselective synthesis and/or to subject the reaction
product to appropriate puri?cation steps so as to produce
substantially stereochemically pure or optically pure materi

optionally fused to a cycloalkyl or aryl group to form a bicy

oms.

centers on, for example, the parthenolide C-11 and thus can

45

The present invention further provides for compounds hav
ing formula (I), or a pharmaceutically acceptable salt thereof,
Wherein Z is a group that is converted to :CH2 under physi
ological conditions during or after administration to a mam

According to a further embodiment of the invention, Z is
i(CH2)miS(O)niRl Where m is an integer from 0 to 4, n is

malian patient, thereby yielding a methylene group. In par

an integer from 0 to 2, Where preferably, R5, R6, R7, R9, and

R10 are H; R4 and R8 are 4CH3; and Z is optionally substi
tuted C1_8 straight-chained or branched aliphatic, optionally

ticular embodiments X1, X2 and X3 are 0; R5, R6, R7, R9, and

R10 are H; and R4 and R8 are each 4CH3. In one particular
embodiment, m is 1. In another embodiment n is 0. In other

containing 1 or more double or triple bonds, Wherein one or

embodiments, R1 is independently selected from hydrogen,

more carbons are optionally replaced by R* Wherein R* is

iCN, optionally substituted C 1 -C4 alkyl or aryl. In particular

optionally substituted cycloalkyl, heterocycloalkyl, aryl or
heteroaryl; an amino acid residue, H, 4CN, 4C(O)i,

embodiments, R1 is selected from iC6H5, iCHZCH
(COZH)(NH2), and iCHZCO2H.
Exemplary compounds of the present invention include:
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1 l S, l l , l 3 -Dihydro, l 3 -dimethylaminoparthenolide

isi, isoi, isozi, iNRli, iSOZNRli,

(DMAPT);

iNRlRZ, or iNRlSOZi, wherein R1 and R2 are indepen
dently selected from H and optionally substituted aliphatic,

l l S, l l , l 3-Dihydro, l 3-diethylaminoparthenolide;
l l S, l l , l 3-Dihydro, l 3-(tert-butylamino)parthenolide;
l l S, l l , l 3-Dihydro, l 3-(pyrrolidin-l -yl)parthenolide;

cycloalkyl, heterocycloalkyl, aryl or heteroaryl. In preferred
embodiments Z is iCH2N(CH3)2, 4CH2N(H)(C(CH3)3),

l l S, l l , l 3-Dihydro, l 3-(piperidin-l -yl)parthenolide (PIPT);
l l S, l 1,13 -Dihydro, l 3 -(morpholin- l -yl)parthenolide;
l l S, l l , l 3-Dihydro, l 3-(4-methylpiperidin-l -yl)partheno

lide (4MEPT);
l l S, l l , l 3-Dihydro, l 3-(4-methylpiperaZin-l -yl)partheno

lide;
l l S, l l , l 3-Dihydro, l 3-(homopiperidin-l -yl)parthenolide;

4C(O)C(O)i, 4C(O)NRli, 4C(O)NR1NR2i, 4C(O)
of, ioqok, iNRlCOZi, foi, iNRlC(O)
NRL, A)C(O)NRli, iNRlNRZi, iNR1C(O)i,
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%H2N(CH2CH3)2, iCH2N(CH2CH:CH2)2, %H2
azetidine, iCHz-pyrrolidine, iCHZ-piperidine, 4CH2-ho
mopiperidine, 4CH2-heptamethyleneimine, iCH2-4-me
thylpiperidine, 4CH2-morpholine, iCHz-pyrrolidine,
4CH2-proline, 4CH2-thiophenol, 4CH2-diethanolamine,
4CH2-hydroxypiperidine, 4CH2-methylhomopiperaZine,
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iCHZ-thiomorpholine, iCHZ-mercaptoacetic acid,
iCHZ-benzylpiperidine, 4CH2-piperidine-4-carboxylic
acid, 4CH2-azetidine-3-carboxylic acid, 4CH2-piperidi
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Scheme I

nylpiperidine, or iCHZ-cysteine.
The present invention further provides for compounds hav
ing formula (I), or a pharmaceutically acceptable salt thereof,
Wherein Z is CH2N(CH3)2 Which under physiological condi

HNRIRZ
solvent, base

tions during or after administration to a mammalian patient,
undergoes mono- or di-demethylation; conversion to :CH2,

temp erature

or cysteine or protein conjugation. In particular embodi

ments, X1, X2 and X3 are 0; R5, R6, R7, R9, and R10 are H; R4
and R8 are iCH3;

The present invention further provides compounds
Wherein the parthenolide based derivatives of formula (I)
form dimers or duplexes With another molecule of formula (I)
or With basic nitrogen-containing synergistic anticancer drug
molecules such as 5-?uorouracil, cytarabine, mytomycin C,
Doxorubicin and Daunorubicin. Accordingly, the present

invention provides compounds of the general formula (II):
20

S cheme II

(11)

solvent,
has e
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temperature

Where L is a linker, as de?ned above, and W is a molecule

With anti-cancer grthh activity. Where W is another par
thenolide derivative of formula (I), the present invention pro

vides compounds of formula (III):
40

In the above scheme, the solvent is selected from a loW alkyl

alcohol, such as methanol, ethanol, propanol, isopropanol,

n-butanol, tert-butanol, and chloroform, methylene chloride,
benzene, toluene, tetrahydrofuran, dioxane, 1,2-dimethoxy
ethane, pyridine, carbon tetrachloride, diethyl ether, tert-bu

Where R'4, R's, R'6, R'7, R's, R'9, R'lo, X'l, X'2 and X'3 are
independently as de?ned above for their counterparts, R6, R7,
R8, R9, R10, X1, X2 and X3; and L is a linker, as de?ned above.
Preferred linkers include optionally substituted alkyl and
amine groups. In one particular embodiment, L is iCHzN

tyl methyl ether and/or the mixture of two or more of the
solvents listed above. The base is selected from a low trialky
60

(R)CH2i, Where R is as de?ned above. Included are phar

maceutically acceptable salts formed With inorganic and/or
organic acids, as de?ned above for compounds of formula (I).
In accordance With another embodiment of the invention,
the methods for the preparation of the amino analogs
described in this invention are disclosed in Schemes I and II.
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lamine, such as trimethylamine, triethylamine, tripropy
lamine, and tributylamine, and pyridine, 2-, 3-, and 4-pi
colines, 2-, 3-, and 4-dimethylaminopyridines. The
temperature is selected from —20° C. to 130° C. The reaction
time required to effect the desired coupling reaction can vary
Widely, typically falling in the range of 30 min to 24 hours.
Puri?cation can be achieved by a variety of techniques, such

as, liquid chromatography through neutral or basic silica gel,
bonded silica gel phases such as octadecylsilica, octylsilica

